Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Blood · 13.03.2023
DOI: 10.1182/blood.2022019254 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Blood, online erschienen am 13.03.2023. Verfasst von Ryan C Lynch und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Concurrent administration pembrolizumab with chemotherapy in untreated classical Hodgkin lymphoma (CHL) has not previously been studied. To investigate this combination, we conducted a single arm study of concurrent pembrolizumab with AVD (APVD) for untreated CHL. We enrolled 30 patients (6 early favorable, 6 early unfavorable, and 18 advanced stage, median age 33 years (range 18-69 years)) and met the primary safety endpoint with no observed significant treatment delays in the first two cycles. Twelve patients experienced grade 3-4 non-hematologic adverse events (AEs) most commonly febrile neutropenia (5, 17%) and infection/sepsis (3, 10%). Grade 3-4 immune-related AEs were seen in 3 patients, including ALT elevation (3, 10%) and AST elevation (1, 3%). One patient experienced an episode of grade 2 colitis and arthritis. Six (20%) patients missed at least one dose of pembrolizumab due to adverse events, primarily grade 2 or higher transaminitis (5, 17%). Among 29 response-evaluable patients, the best overall response rate was 100% and CR rate of 90%. With median follow up of 2.1 years, 2-year progression-free survival (PFS) and overall survival were 97% and 100%, respectively. To date, no patient who withheld or discontinued pembrolizumab due to toxicity has progressed. Clearance of ctDNA was associated with superior PFS when measured after cycle 2 (p=0.025) and at end of treatment (EOT, p=0.0016). None of the 4 patients with persistent disease by FDG-PET at EOT yet negative ctDNA have relapsed to date. Concurrent APVD shows promising safety and efficacy, but may yield spurious PET findings in some patients. Trial Registration Number: NCT03331341
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, University of Washington, Seattle, WA.
- Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.
- Division of Oncology, Stanford University, Stanford, CA.
- Department of Radiology, University of Washington, Seattle, WA.
- Department of Radiation Oncology, University of Washington, Seattle, WA.
ORCID-Profile: Ryan C Lynch, Edus H Warren, Stephen D Smith, Mazyar Shadman, Ash A Alizadeh, Avanti Gulhane, Delphine L Chen
Förderung
- NCI NIH HHS
Zitieren
APA
Lynch, R. C., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Till, B., Raghunathan, V. M., Alig, S., Alizadeh, A. A., Gulhane, A., Chen, D. L., Tseng, Y., Coye, H., Shelby, M., Ottemiller, S., Keo, S., Verni, K., Du, H., …, & Gopal, A. K. (2023). Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood.2022019254
Vancouver
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, et al. Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood. 2023. doi:10.1182/blood.2022019254
BibTeX
@article{Lynch2023,
author = {Lynch, Ryan C and Ujjani, Chaitra S and Poh, Christina and Warren, Edus H and Smith, Stephen D and Shadman, Mazyar and Till, Brian and Raghunathan, Vikram M and Alig, Stefan and Alizadeh, Ash A and Gulhane, Avanti and Chen, Delphine L and Tseng, Yolanda and Coye, Hilary and Shelby, Megan and Ottemiller, Susan and Keo, Sarith and Verni, Kaitlin and Du, Hongyan and Vandermeer, Jacquelin and Gaston, Ashley and Rasmussen, Heather and Martin, Paul and Marzbani, Edmond and Voutsinas, Jenna and Gopal, Ajay K},
title = {Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022019254}
}
EUVIMED